Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina
Acute coronary syndrome (ACS) is one of the most critical clinical syndromes and rupture of vulnerable plaque in the coronary artery is considered to be responsible for the pathogenesis of acute coronary syndrome [1] . Studies have shown the process of in ammation a ects the stability of the atherosclerotic plaque and may be the initiating link of the early stages of atherosclerosis [2] . Recent studies suggest that the pro-in ammatory cytokine interleukin family plays an important role in the pathogenesis of atherosclerosis [3] . Interleukin-33 (IL-33), a new member of the IL-1 superfamily of cytokines [4] , is essential in the regulation of the in ammatory response as well as in congenital and acquired autoimmune diseases [5] . It has been found that expression of IL-33 in human atherosclerotic plaques is associated with plaque instability [6] . Interleukin-6 (IL-6) is a pro-in ammatory cytokine that is triggered by vulnerable plaque or necrotic myocardium and correlates with the severity of coronary artery disease (CAD) [7] .
is study measured the serum levels of IL-33 and IL-6 in patients with ACS or SAP. At the same time, coronary angiography was performed in patients with CAD to investigate the relationship among IL-33, IL-6 and the severity of coronary lesions.
Methods
Subjects e study was approved by the Institution Review Board of the First A liated Hospital of Zhengzhou University. Informed consent was obtained from all participants before the study.
From 1 August 2012 to 28 February 2013, 83 consecutive patients (54 men, mean age 56.50 ± 12.54 years, range 40-78) with coronary artery disease, con rmed by coronary angiography, were recruited from the Department of Cardiology in the First A liated Hospital of Zhengzhou University. All the enrolled patients were classi ed into two groups: a group with ACS and a group with SAP. e ACS group consisted of 16 patients with ST elevation acute myocardial infarction (STEMI) and 24 patients with unstable angina pectoris (UAP). e SAP group consisted of 43 patients with stable angina pectoris. Percutaneous Coronary Intervention (PCI) was performed in 83 patients with ACS and SAP.
irty healthy subjects (17 men, mean age 51.50 ± 12.81 years, range 42-76) with no signs of ischemic heart disease, ECG criteria suggestive of acute coronary syndrome or past history of cardiovascular disease or diabetes were also recruited for the measurement of serum levels of IL-33 and IL-6. Diagnostic criteria of STEMI include detection of rise of cardiac biomarker values (troponin I (TnI), troponin T (TnT), or CK-MB) with at least one value above the 99th percentile of the upper reference limit and with at least one of the following: symptoms of ischemia; new or presumably new signi cant ST-T changes or new LBBB; development of pathological Q waves in the ECG; imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality; and, identication of an intracoronary thrombus by angiography [8] . UAP was de ned as chest pain at rest with either a ST segment depression of at least 0.1 mV or a T-wave inversion in two or more continuous electrocardiographic leads. No biomarker of myocardial necrosis has been released (based on two or more samples collected at least 6 h apart, with a reference limit of the 99th percentile of the normal population) [9] . SAP was diagnosed as chest pain of at least six months' duration accompanied by evidence of severe coronary artery disease on coronary angiography and by the absence of clinically evident ischemic episodes during the week preceding arteriography [10] .
ose who had a previous history of cardiomyopathy, valvular heart disease, tumor, in ammatory diseases, liver and renal dysfunction, cerebral vessel diseases or peripheral angiopathy were excluded from the study, as were those who were pregnant.
Both STEMI and UAP patients were managed with intravenous heparin before PCI. Other drugs used in all three groups of patients included β-blockers, aspirin, nitrates, statins and angiotensin converting enzyme inhibitors.
Detailed self-reported questionnaires containing information on the history of hypertension, smoking status, alcohol consumption and so on were collected at baseline and used for analysis. Clinical ndings, such as blood pressure and heart rate, were assessed upon hospital admission by the internal medicine doctor.
Blood samples to be used for assessment of serum IL-33 and IL-6 levels were drawn a er admission within 60 minutes, into tubes containing EDTA and aprotinin immediately centrifuged for 10min at 1000 x g at 4 °C and stored at -80 °C until assayed in a blinded fashion in a single batch. Samples were thawed only once. Blood to be used for assessments of serum high-density lipoproteins, low-density lipoproteins, total cholesterol, triglyceride, NT-proBNP, CK-MB and high-sensitivity C-reactive protein (hs-CRP) levels was drawn into tubes containing anticoagulant and the tubes were then sent to the clinical laboratory for determination.
Measurements of IL-33 and IL-6
Levels of serum IL-33 and IL-6 were determined using ELISA kits (Nanjing Jiancheng Technology Industry Co. Ltd, Nanjing, China). e antibodies were coated onto microlite ELISA plates using 10 μL per well in 100 μL of phosphate-bu ered saline. Plates were then blocked in bovine serum albumin and wells were lled with 40 μL IL-33 or IL-6 plasma samples or recombinant standards. A er incubation overnight, the plates were washed and then incubated with anti-IL-6 or anti-IL-33 in an assay bu er, per 100 μL in each well. A er 2 hours, plates were washed, and detection was with methyl acridinium esterlabeled streptavidin. ese assay kits had a lower limit of detection of 5 ng/L for IL-33 and 2 ng/L for IL-6. Experiments were performed in triplicate.
Echocardiographic study
Two-dimensional echocardiography was carried out using a digital imaging system (Vivid-7; GE Medical System). e le ventricular end-systolic volume (LVESV) and the le ventricular end-diastolic volume (LVEDV) were measured using Simpson's method, and the le ventricular ejection fraction (LVEF, %) was calculated by (LVEDV -LVESV)/LVEDV × 100%.
Coronary angiography
Coronary angiography was performed using a approach of the radial artery with six Fr diagnostic catheters. Images were recorded in multiple projections for le and right coronary arteries on 35 mm cine lm. All coronary stenoses were assessed by two experienced cardiologists who had knowledge of neither the levels of IL-33 and IL-6 nor the identity and clinical characteristics of the patients. 
Results

General characteristics of the study subjects
Demographic and clinical characteristics of the study participants are shown in Table 1 . Among the three groups, there was no signi cant di erence in sex, age, smoking history, family history of coronary artery disease or diabetes, blood pressure, heart rates and blood cholesterol levels. A greater number of patients with ACS had hypertension compared with those in the SAP group (P<0.05); meanwhile, a greater number of patients with SAP had hyperlipidemia compared with ACS group (P<0.05).
Comparisons of the mean levels of serum IL-33 and IL-6
Comparisons of serum levels of IL-33 and IL-6 and other biochemical features and le ventricular function among patients with ACS or SAP and healthy controls are shown in Table 2 .
e level of IL-33 in ACS group was lower than the SAP and control group (P<0.01), and the level of IL-6 in the ACS group was higher than the SAP and control group (P<0.01).
ere was no di erence in serum IL-6 level between the SAP and control groups and there was no di erence in hs-CRP, NT-proBNP, CK-MB or echocardiographic parameters among the three groups. e Gensini score, an indicator of the degree of coronary atherosclerosis, was higher in the ACS group than in the SAP group, but the di erence was not signi cant (P = 0.178).
Relationship between serum levels of IL-33 and IL-6 and severity of vascular lesions
e serum levels of IL-33 and IL-6 in single-, double-and triple-vessel disease groups were higher than that in the control group (P<0.05); however, there was no di erence in the serum levels of IL-33 and IL-6 among the three patient groups ( Table  3) .
Correlations of IL-33 and IL-6 in ACS and SAP group
In patients with ACS, the level of IL-33 showed a negative correlation with the level of serum IL-6 (r = -0.871, P<0.01; Figure 1) . Similarly, in the SAP group, the level of IL-33 was also Figure 2) . Discussion e in ammatory response plays an important role in the development of ACS. Based on the consensus that the in ammatory response is the cause of instability of coronary plaque, resulting in the pathogenesis of ACS, researchers have conducted extensive studies on a variety of in ammatory markers, including IL-1, IL-6 and hs-CRP, and found that they all play a role in the pathogenesis of ACS. Studies of AMI suggest that cytokines are preferentially produced by in ammatory cells in the pre-infarct zone and that persistent elevation of cytokines results from an increased in ltration of in ammatory cells [11] ; however, the nature of the relationships among various cytokines in the in ammatory reaction are still unclear.
is is the rst study assessing the correlation of IL-33 and IL-6 levels in patients with ACS or SAP. e major ndings of the this study are as follows: 1) the serum level of IL-33 in the ACS group was lower than either the SAP group or the health subjects and the serum levels of IL-6 showed the opposite tendency; 2) the serum levels of IL-6 were similar between patients with SAP and health subjects; 3) there were no di erences in serum levels of IL-33 or IL-6 among patients with single-, double-or triple-vessel lesions; and, 4) the IL-33 levels were negatively correlated with IL-6 levels in the ACS and SAP groups.
IL-33, a recently described member of the IL-1 family, has been reported to be the natural ligand for membrane-bound ST2. IL-33 is broadly expressed in many tissues, including the heart, and Sanada et al. [12] found it to be a biomechanicallyinduced protein predominantly synthesized by cardiac broblasts. It was recognized as one of the key cytokines enhancing the 2-type immune responses and had been shown to promote the production of 2 cytokines, such as IL-4, IL-5 and IL-13, by innate-type lymphoid cells, basophils, mast cells, and 2 cells [13, 14] . A study by Milovanovic et al. [15] suggested that ST2 alters the 1/ 2 balance and leads to enhanced 1/ 17 immune response; in addition, the fact that strong pro-in ammatory type of ST2 -/-antigen-presenting cells is accompanied by higher production of IL-33 indicates that IL-33 exhibits an intracrine in ammatory role in APC and may therefore promote in ammation. Furthermore, McLaren [16] revealed that IL-33 signi cantly reduced the mRNA expression of key genes implicated in the uptake and e ux of cholesterol (like SR-A, CD36 and SR-B1) in THP-1 macrophages and primary human monocyte-derived macrophages (HMDMs) and simultaneously increases gene expression involved in cholesterol e ux, including Apolipoprotein E, therefore decreased AcLDL/OxLDL uptake and enhances cholesterol e ux. In summary, IL-33 plays an important role in the cardiovascular system and IL-33/ST2 signaling was revealed as a crucial cardioprotective broblast-cardiomyocyte paracrine system. Miller [17] also found, in mice de cient in apolipoprotein E, that administration of recombinant IL-33 induced 2 cytokines and protective ox-LDL antibodies, which signicantly reduced atherosclerotic plaque development and exerted cardioprotective e ects. ese results demonstrate a novel role for IL-33 in the control of 1/ 2 balance and indicate that IL-33 may be used as a new biomarker for the severity of coronary heart disease and may also be a potential therapeutic target for patients with ACS or SAP. e results of this study demonstrate that IL-33 levels decreased as clinical severity increased from SAP to ACS, suggesting that IL-33 might re ect the severity of CAD. Further studies should be conducted to investigate the correlation between level of IL-33 and stability of atherosclerotic plaques.
In the current study, a higher serum concentration of the pro-in ammatory cytokine IL-6 was found in the ACS group in comparison with the SAP and control groups, which is consistent with the results of earlier studies [18, 19] . IL-6 is a proximal mediator produced under di erent stimuli, such as IL-1β, in various tissues [20] . During tissue injury or infection, IL-6 is mainly produced by hepatocytes as the major initiators of the acute-phase reaction [21] . In patients with CAD, elevated circulating IL-6 concentrations may be the result of a variety of stimuli, including various clinical risk factors that lead to the release of IL-6 from numerous cell types, including smooth muscle cells and macrophage/foam cells found in atheromatous plaques [22] . Anderson et al. [18] reported that IL-6 and the soluble IL-6 receptor (sIL-6R) were elevated and IL-6R mRNA was decreased in patients with AMI, in comparison with patients with CAD and controls, supporting the hypothesis that blocking IL-6 receptor binding may be pathogenic in AMI. Several lines of evidence suggest that IL-6 may be used as a biomarker for evaluating the severity and prognosis of coronary heart disease. López-Cuenca et al. [19] demonstrated that IL-6 concentrations decreased a er the acute phase of CAD and that obtaining serial measurements of IL-6 concentration improved the prognostic risk strati cation of patients with CAD. A study by Ammirati [23] suggested that IL-6 + STEMI patients were at an increased risk of death and that determination of the combined cytokine index may improve the prediction of fatal outcomes. Considerable evidence has been obtained for the diagnostic and prognostic role of IL-6 in patients with CAD [24] .
is study also detected a negative correlation between levels of IL-33 and IL-6 in patients with ACS and SAP although it is unclear how the two cytokines a ect each other. Previous studies, in primary blood-derived human basophils, have demonstrated that IL-33 induces modest production of multiple cytokines, including IL-4, IL-5, IL-6, IL-8, IL-13 and GM-CSF [25, 26] . Basophils are functionally related to mast cells and are targets of IL-33. Following IL-33 stimulation, basophils produce several cytokines, particularly IL-4, IL-6 and IL-13, which enhance basophile adhesion, integrin expression, chemotaxis, degranulation and survival [25, 27] . IL-33 can also activate dendritic cells (DCs) to produce IL-5, IL-6 and IL-13 by CD4+ T cells [28] , suggesting an additional indirect role of IL-33 in the production of IL-6; therefore, IL-33 may increase the availability of IL-6 in the process of in ammation. Increased level of IL-6 may also exert a negative e ect on the level of IL-33, but the mechanism of this process needs to be further investigated.
is is the rst study that investigates the correlation between levels of IL-33 and IL-6 in patients with ACS and SAP and the results suggested that IL-33 and IL-6 are both involved in the pathogenesis of ACS and may have mutual e ects with each other. us, both IL-33 and IL-6 show promise as new biomarkers for the evaluation of severity of CAD and may be associated with stability of vulnerable plaques.
In conclusion, our study demonstrates that, in patients with ACS, there is a decreased serum level of IL-33 and an increased serum level of IL-6. A negative correlation was found between IL-33 and IL-6 levels in the ACS and SAP groups. IL-33 and IL-6 show promise for use as biomarkers for evaluating in ammatory response and severity of CAD in patients with ACS or SAP. e interaction among di erent cytokines remains to be investigated.
is study has several limitations. First, it was conducted at a single center and the number of cases was relatively small. Second, it did not assess long-term e ects on atherosclerotic plaque progression and the scale of in-stent restenosis. ird, it did not compare levels of IL-33 and IL-6 at di erent time points. us, further studies should involve a larger number of cases at di erent time points and a longer follow-up on all patients in the study.
